INNOVA’s French seed capital company, INVENT, has been contributing to the success of Media Pharma, one of INVENT’s most promising start-ups. After being the subject of a TV coverage  il Sole 24 Ore, the principal business newspaper in Italy has dedicated an article on MediaPharma’s activities and success story.

Although Media Pharma is a young spin-off created  in April 2009, it already has acquired extensive scientific and national research attention  in the biopharmaceutical field specializing in developing innovative therapies for cancer treatment. The company focuses on the discovery, development and commercialization of monoclonal antibodies for the diagnosis and treatment of cancer and other diseases with unmet medical need and collaborates with reputed research institutions such as the Max Planck Institute in Martinsried (Germany) and the University of Pittsburgh (USA).

Read the article in the official webpage of the newspaper.